Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00888940 · ClinicalTrials.gov registry record · Phase 2
Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery
A Phase 2 study of Blood Loss and Surgical Procedures, Operative, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 2
- Development phase
- 243
- Enrollment target
- 20
- Study locations
NCT00888940: Completed Phase 2 study of Blood Loss and Surgical Procedures, Operative, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
NCT00888940 is a Phase 2 study of Blood Loss and Surgical Procedures, Operative that has completed, run by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 243 participants, above the 160-participant average among 9 other Blood Loss trials with a reported enrollment target (52% higher). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00888940, a Phase 2 study of Blood Loss and Surgical Procedures, Operative, has completed, sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 243 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects Exposed to Cardio-pulmonary Bypass During Cardiac Surgery at High Risk of Bleeding
Conditions Studied
Interventions
- DRUG Ecallantide
- DRUG Cyklokapron(R)
Study Locations (20)
Other
- Universitaetsklinikum Aachen AoeR - Aachen
- Klinikum Augsburg - Augsburg
- Herz- und Gefaesszentrum Bad Bevensen - Bad Bevensen
- Universitaetsklinikum Bonn - Bonn
- Klinik und Poliklinik fuer Herz- und Thoraxchirurgie der Universitaet zu Koeln - Cologne
- St. Johannes Hospital - Dortmund
- Herzzentrum Dresden GmbH Universitaetsklinik - Dresden
- Universitaetsklinikum Erlangen - Erlangen
- Universitaetsklinikum Frankfurt - Frankfurt
- Universitaetsklinikum Freiburg - Freiburg im Breisgau
- Universitaetsmedizin Goettingen - Göttingen
- Universitaetsklinikum Halle (Saale) - Halle
- Universitaeres Herzzentrum Hamburg GmbH - Hamburg
- Universitaetsklinikum Heidelberg - Heidelberg
- Herzzentrum Leipzig GmbH - Leipzig
- Klinikum der Stadt Ludwigshafen gGmbH - Ludwigshafen
- Klinik fuer Herzchirurgie des Universitaetsklinikum SH - Lübeck
- Deutsches Herzzentrum Muenchen - Munich
- HELIOS Klinik Wuppertal - Wuppertal
Alabama
- Cardio-Thoracic Surgeons PC - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 243 participants |
| Start Date | 2009-06 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)42 total trials
What the finished NCT00888940 record still lists
NCT00888940 is an interventional study that assigns participants to a tested intervention. The registered 243 participants enrollment target is mid-sized for trials with a published cap, above the 160-participant average among 9 other Blood Loss trials with a reported enrollment target (52% higher).
The record links to 2 conditions, with Blood Loss appearing as the primary indexed condition, and to 2 interventions - of which Ecallantide is the first listed.
NCT00888940 names 20 study sites across 2 states, led by Other, Alabama.
Frequently Asked Questions
What is clinical trial NCT00888940 about?
NCT00888940 is a clinical study titled "Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery". A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects Exposed to Cardio-pulmonary Bypass During Cardiac Surgery at High Risk of Bleeding
What is the current status of trial NCT00888940?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 243 participants. The study started on 2009-06. Estimated completion is 2010-01.
What conditions does trial NCT00888940 study?
This clinical trial studies the following conditions: Blood Loss, Surgical Procedures, Operative.
What interventions are being tested in trial NCT00888940?
The interventions under investigation include: Ecallantide (DRUG), Cyklokapron(R) (DRUG).
Who is sponsoring clinical trial NCT00888940?
This trial is sponsored by Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00888940 being conducted?
This trial has 20 study locations across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00888940's enrollment target sits among peer trials
243 4th of 9 higher than 6 of 9 other Blood Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Blood Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oxytocin Pharmacokinetics and Pharmacodynamics
RECRUITING · Phase 2
-
Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation
COMPLETED · Phase 2
-
Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery
COMPLETED · Phase 2
-
Tranexamic Acid for Second Trimester Dilation and Evacuation and Bleeding Outcomes
RECRUITING · Phase 4
-
Extended Postoperative Oral Tranexamic Acid in Knee Replacement
ACTIVE NOT RECRUITING · Phase 4
-
LBNP Tolerance With Skin Warming After Exercise Cold Stress
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06253871 · 243 participants · Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
- NCT06289491 · 243 participants · NA
A Trial of Hydrus Microstent Versus Goniotomy
- NCT06536296 · 243 participants · NA
The Impact of Music Medicine on Preterm Brain Development and Behavior
- NCT06907615 · 243 participants · Phase 2
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia